GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control
Video navigation menu
Refresher of the incretin effect in healthy subjects 0:54
How to normalize the impaired incretin effect seen In T2DM patients? 6:27
GLP-1 has effects in multiple organs 8:37
How do the multiple effects of GLP-1 analogues translate into clinical endpoints? 13:41
How to use GLP-1RA in clinical practice? 14:41
Educational information
This lecture was part of a CME accredited symposium: "Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice?", held during ESC 2018 in Munich, Germany.
Faculty
Filip K. Knop, MD, PhD - endocrinologist, University of Copenhagen, Denmark
Disclosures
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk
Online-CME
This is available as accredited online CME for members. Click the button below to enroll:
EnrollThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: